Drugs / EC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07152639 | Aug 2025 → May 2026 overdue | tuberculosis | Chengdu CoenBiotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07152639 ↗ |
| Modality | Protein / enzyme biologic | “marketed recombinant Mycobacterium tuberculosis fusion protein (EC)” NCT07152639 ↗ |
| Route | Other | “single intradermal injection” NCT07152639 ↗ |